SYK and acute lymphoblastic leukemia: Recently, in a study focused on its anti-inflammatory effects, a brusatol derivative was shown to inhibit the spleen tyrosine kinase (SYK) [38], a kinase whose constitutive activation and associated signaling inhibition was already demonstrated in B-ALL with KMT2A rearrangements [39].